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The aim this study was to determine the in vitro susceptibility to fosfomycin of bacteria iso-
lated  from urine samples of pregnant women with urinary tract infection. Samples of urine
culture with bacterial growth of pregnant women were collected from clinical laboratories in
Tubarão, state of Santa Catarina, Brazil, between September 2012 and May 2013. In the exper-
imental stage, the colonies were tested for sensitivity to fosfomycin by using the Kirby–Bauer
method. The following information relating to the samples was also collected: patients’ age,
colony count, type(s) of identiﬁed bacterial(s) and result of the antimicrobial sensitivity test.
Student’s t-test was used for mean comparison. A total of 134 samples were selected for
the  study. The age of the subjects ranged from 15 to 40 years (mean 26.7). Escherichia coli
(Gram-negative) and Staphylococcus aureus (Gram-positive) were the most commonly identi-
ﬁed  species. In 89% of cases, the microorganisms were sensitive to fosfomycin. E. coli and S.
aureus were the main species of bacteria responsible for urinary tract infections in women inthe  study area. The most prevalent microorganisms in pregnant women with urinary tract
infection were susceptible to fosfomycin.
© 2015 Published by Elsevier Editora Ltda.
of an antimicrobial agent to treat UTI during pregnancy is
complex because it requires full attention to maternal andrinary tract infections (UTI) are common during pregnancy
ue to hormonal and anatomo-physiological changes that
acilitate the growth and dissemination of bacteria in the
aternal urinary tract.1 It is estimated that 5–10% of women
evelop some kind of UTI during pregnancy.2 Asymptomatic
acteriuria is the most common situation, followed by acute
ystitis and pyelonephritis.3 These infections have potentially
erious consequences for maternal and fetal health if they are
ot properly treated.1
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413-8670/© 2015 Published by Elsevier Editora Ltda.The choice of antimicrobial agents should preferably
consider the urinalysis results, which allow for pathogen iden-
tiﬁcation, in addition to antimicrobial susceptibility testing
that indicates the susceptibility of microorganisms to spe-
ciﬁc groups of antimicrobials.4 However, the correct choiceehon, Tubarão, Santa Catarina 88704-900, Brazil.
fetal safety, in addition to ease of use, access, and cost of
treatment.5
i s . 2 0320  b r a z j i n f e c t d 
Knowing the sensitivity of the etiological agents against
antimicrobial drugs available, linked to relevant epidemiolog-
ical data, helps to make appropriate therapeutic decisions
based on updated scientiﬁc information for adequate treat-
ment, which shortens the symptomatic period and prevents
the possibility of recurrences and complications. However,
in recent years, the problem of antimicrobial resistance has
become very common, mainly because the antimicrobials
once so successful, are no longer effective against several
bacterial species responsible for infections in the urinary
tract.3–6
Although the introduction rate of new classes of antibiotics
on the market is limited, some old drugs such as fosfomycin
can still provide a temporary solution to the emerging problem
of resistance, since they have proven to be effective against the
prevailing pathogens.
The aim of this study was to demonstrate the in vitro
antibacterial susceptibility to fosfomycin of bacteria taken
from urine samples of pregnant women with UTI.
This study was approved by the Research Ethics Committee
of the University of Southern Santa Catarina in November 29,
2012 (code number 12.289.4.01.III).
The study was conducted in two stages: ﬁrst, an epidemi-
ological cross-sectional study to collect data related to urine
cultures of pregnant women performed in laboratories of the
city of Tubarão, Santa Catarina, Brazil, between September
2012 and May 2013; in the second stage, in vitro antibacterial
susceptibility to fosfomycin of isolated bacterial colonies from
the urinary tract of pregnant women was evaluated.
Thus, the samples consisted of positive urine cultures
obtained from the participating laboratories, as well as the
following information contained in the reports or patients’
records: colony count, identiﬁcation of isolated species,
antimicrobial susceptibility of the tested agents, and age of
pregnant women.
The sample size was calculated according to the average
annual number of live births in that city, which was 2470, and
represented the estimated total number of annual pregnan-
cies in the last decade (2001–2010), according to data from the
Information System on Live Births.
The study sample was collected during nine months, and
the ﬁnal sample size of 186 pregnant women took into account
the average annual number of pregnancies adjusted for the 9-
month period (1853 pregnancies), and the percentage of UTI
in pregnancy of 10%, as reported in the literature.2 For a con-
ﬁdence level of 95%, a minimum of 126 urine samples would
have to be obtained.
The inclusion criteria included positive urine culture of
pregnant women living in the city of Tubarão, Santa Cata-
rina, according to Kass’ classiﬁcation, regardless of symptoms.
There was no access to clinical information regarding the
patients’ signs and symptoms. Samples characterized by
dehydrated cultures were excluded from the study because
of possible contamination by non-pathogenic environmental
fungi or other contaminant external agents. Cultures in which
the necessary information was unavailable or inaccessible for
any reason were excluded as well.
Information about the age of participating pregnant
women, date of urine culture, and date of birth were retrieved
from records and reports of the participating laboratories. 1 5;1  9(3):319–323
The selected samples were tested for sensitivity to
fosfomycin by the disk diffusion method known as the
Kirby–Bauer method, as recommended by the Clinical and
Laboratory Standards Institute, described in document M100-
S23, as of January 2013, and based on studies of Minimum
Inhibitory Concentration. The disc used was SENSIBIODISC
CECON Fosfomicina® for antibiogram in standard concentra-
tion of 200 mcg  of the drug, approved by the Brazilian Ministry
of Health (Registration No. 10000600103) for testing Gram-
positive and Gram-negative bacteria isolated from human
urinary tract.
All data obtained in both stages of the study were organized
and stored in Excel spreadsheet (Microsoft Ofﬁce 2010) and
analyzed with the use of descriptive statistics, and presented
in a narrative, tabular, or graphical form. Statistical analysis
was performed using the Statistical Product for Service Solu-
tions v.20.0. Student’s t test was used for mean comparison.
The conﬁdence level was set at 95%.
A total of 139 samples were selected for the study, of which
ﬁve (3.6%) were excluded; three because of contamination and
two due to lack of laboratory antimicrobial susceptibility test-
ing results.
The age of participants ranged from 15 to 40 years (mean
26.7; SD 6.2). The most commonly identiﬁed microorganism
was Escherichia coli (66.2%), followed by Staphylococcus aureus
(14.3%), Klebsiella pneumoniae (3.8%), Enterobacter (3.0%), and
others (12.7%).
The antimicrobial agents tested for antimicrobial sen-
sitivity included nalidixic acid, ampicillin, sulphazotrim,
ciproﬂoxacin, norﬂoxacin, and nitrofurantoin (Table 1).
Eighty-nine percent of the microorganisms were sensitive
to fosfomycin. Intermediate or resistant isolates included the
strains of E. coli (5.9%; n = 8), S. aureus (2.2%; n = 3), Staphylococcus
sp. (1.5%; n = 2), Enterococcus sp. (0.7%; n = 1), and Staphylococcus
saprophyticus (0.7%, n = 1).
The mean age of pregnant women with UTI caused by
microorganisms sensitive to fosfomycin was 26.6 years (SD
6.2), whereas the mean age of those with UTI caused by resis-
tant microorganisms was 27.2 years (SD 6.3), [p = 0.731].
Relative sensitivity of the two most commonly isolated
bacteria in this study to the orally administered antimicrobials
safe for use during pregnancy is shown in Table 2.
E. coli was the most commonly identiﬁed microorganism,
which supports the ﬁndings of other studies that indicate
the predominance of this species in community-acquired
UTIs among pregnant and non-pregnant women of different
age-groups.2,4–7 E. coli, in addition to be part of the normal
intestinal microbial ﬂora, is able to invade and remain in the
urinary tract due to structural factors that facilitate adher-
ence, which justify its predominance when compared to other
species of the same family (Enterobacteriaceae), also causing
UTI.8
Among the Gram-positive microorganisms, about 15% of
the samples revealed the presence of S. aureus as the etio-
logic agent of UTIs. A study performed in a health center in
Curitiba, Paraná that evaluated 120 urine samples of men  and
women with suspected UTI found a prevalence rate similar
to that of this study, and S. aureus was isolated in 18.2% of
cases.9 However, these ﬁndings differ from those of other stud-
ies in Portugal that found 0.9% of S. aureus in urine samples of
b r a z j i n f e c t d i s . 2 0 1 
Table 1 – Results of antimicrobial susceptibility testing
based on the sensitivity percentage and number of
tested samples (n = 134).
Antimicrobial agents Sensitivity
(%)
Number of samples
tested (n)
Aztreonan 100.0 2
Cefazolin 100.0 1
Cefepime 100.0 22
Ceftriaxone 100.0 6
Ertapenem 100.0 1
Linezolid 100.0 1
Merapenem 100.0 3
Oxacillin 100.0 2
Penicillin G 100.0 2
Piperazobactan 100.0 4
Vancomycin 100.0 2
Cefoxitin 97.4 39
Cephalexin 95.6 23
Norﬂoxacin 94.4 72
Ciproﬂoxacin 93.9 131
Imipinen 91.9 37
Cefadroxil 90.0 50
Chloramphenicol 90.0 10
Fosfomycina 89.0 134
Levoﬂoxacin 88.0 50
Tetracycline 87.5 24
Amoxicillin/clavulanic acid 80.0 5
Nitrofurantoin 72.2 126
Sulphazotrin 71.8 117
Ampicillin 62.9 62
Cephalothin 53.6 28
Nalidixic acid 50.0 60
Pipemidic acid 28.8 59
Gentamicin 24.4 45
Amikacin 20.0 35
Amoxicillin 10.5 38
Erythromycin 0.0 1
a Result obtained in the experimental stage of the study.
Table 2 – Relative sensitivity proﬁle of Escherichia coli and Staph
group of antimicrobial drugs safe for use during pregnancy.
Antimicrobial agents S 
n (%)
Escherichia coli
Cephalexin 93.3 
Fosfomycin 90.9 
Cefadroxil 88.9 
Amoxicillin/clavulanic acid 80.0 
Ampicillin 64.9 
Amoxicillin 13.6 
Staphylococcus aureus
Cefadroxil 100.0 
Cephalexin 100.0 
Fosfomycin 84.2 
Ampicillin 83.3 
Amoxicillin 7.1 
Amoxicillin/clavulanic acid NA 
S, sensitive; R/I, resistant or intermediate.5;1 9(3):319–323 321
uncomplicated cystitis in women, and 2.1% in urine samples of
patients from a pathology service, which can be explained by
the fact that S. aureus has been considered rare in community-
acquired ITUs. In general, they are responsible for less than 4%
of cases.10
Contradictory ﬁndings require clariﬁcation through new
epidemiological studies in the geographic areas under
scrutiny. This study did not aim to examine the criteria
and methods for bacterial identiﬁcation in the laboratories
involved, which characterizes one of its limitations.
In this study, fosfomycin was effective in vitro useful
against most strains and identiﬁed bacteria, which supports
the ﬁndings of several other authors in similar studies11–13
and suggests a possible effectiveness in vivo. Andrade and
collaborators have obtained 88% of UTI clinical cure among
pregnant women through a single-dose oral administration of
three grams of fosfomycin trometamol. They also found that
the dose did not affect the development of fetuses and that
adverse effects occurred in less than 10% of cases, limited to
nausea or vomiting.14 In other clinical study, the treatment of
cystitis in pregnant women with a single dose of fosfomycin
trometamol was as effective as multiple doses. This medica-
tion is the preferred treatment of choice due to its ease of
use.15
Fosfomycin has a bactericidal effect by inhibiting pep-
tidoglycan synthesis and blocking the formation of N-
acetylmuramic acid. Its wide spectrum of action reaches the
target site in Gram-positive and Gram-negative bacteria.16 A
single dose of fosfomycin is usually effective for the treatment
of uncomplicated UTIs.17 Moreover, it is classiﬁed as a preg-
nancy category B drug by the Food and Drug Administration,3
which means that it is quite safe during pregnancy.
With regard to the performance of other antimicrobials,the analysis was focused on the most widely prescribed oral
drugs for pregnant women, according to the literature. The
most reliable medications include penicillin, cephalosporin
ylococcus aureus compared to the orally administered
R/I n Duration of treatment
6.7 15 10 days
9.1 88 Single dose
11.1 27 3 days
20.0 5 7–10 days
35.1 37 7–14 days
86.4 22 7–10 days
0 6 3 days
0 2 10 days
15.8 19 Single dose
16.7 6 7–14 days
92.9 14 7–10 days
NA – 7–10 days
i s . 2 0
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and related compounds, which have low toxicity, even though
they may cause unpredictable allergic reactions.18 Nitrofu-
rantoin has been shown to be effective, but it is associated
with hemolytic anemia of the newborn when used in the last
trimester of gestation, although it is the most appropriate
choice in the case of recurring infections.19 Quinolones are
a pharmacological alternative, because they are classiﬁed as
a pregnancy category B drug by the Food and Drug Admin-
istration, although its use is controversial because of the
risk of damage to fetal cartilage and joint development.20,21
In this study, ciproﬂoxacin had a similar effect to that of
fosfomycin. Contrastingly, the percentage of bacterial resis-
tance to nitrofurantoin was almost one-third of the samples
tested.
The present study found that amoxicillin associated
with a clavulanic acid (beta-lactamase inhibitor) showed
low performance for S. aureus, because the percentage of
antibiotic-resistance was relatively high. Laboratories do not
commonly test amoxicillin associated with beta-lactamase
inhibitor, and this is a limiting factor for the conclusions of
this study.
E. coli was resistant to amoxicillin, as well as to ampi-
cillin, showing a high rate of resistance (above 20%). On
the other hand, the sensitivity rate to cephalosporins and
amoxicillin associated with clavulanic acid was equal to
or above 80%. However, the number of samples tested for
the latter was small, making the comparative analysis with
fosfomycin less valid. It is noteworthy that the appear-
ance of strains that produce beta-lactamases of an extended
spectrum has increased among community- and nosocomial-
acquired enterobacteria.22
It should be emphasized that none of the participating
laboratories included fosfomycin on the list of antimicrobial
agents for performing antimicrobial susceptibility testing of
isolated bacteria. The results presented here were obtained in
the evaluation phase of this study.
In the context of a rational use of antimicrobial agents,
the drug choice has to take into account its efﬁcacy, safety,
convenience, and access. This means that the rational use of
medications occurs when patients receive medications appro-
priate to their clinical needs, in doses that meet their own
individual requirements, for an adequate period of time, and
at the lowest cost to them and their community. In this sense,
the inclusion of fosfomycin in antimicrobial susceptibility
testing of urine cultures performed in clinical laboratories
could predict whether it would be useful as a therapeutic
option for UTI treatment, since this test shall guide the antibi-
otic therapy.
It should be noted that the study was focused on the infor-
mation provided by participating laboratories without direct
contact with pregnant women whose samples were included
in the analyses. Therefore, further clinical data on patients,
such as previous antibiotic use, gestational age, comorbidi-
ties, and in particular, the therapeutical procedures were not
collected or analyzed. Those information items could be asso-
ciated with clinical response and possible outcomes, such as
relapse or reinfection. Thus, the effectiveness of fosfomycin
in vivo could not be ultimately veriﬁed, with a better under-
standing of the interfering aspects and other elements related
to individual situations. 1 5;1  9(3):319–323
The results of this study maintain fosfomycin as an option
of choice for empiric use in cystitis among pregnant women,
as recommended by the guidelines of the Brazilian Society of
Infectious Diseases and the Brazilian Society of Urology. In
most cases, empirical therapy is necessary to accelerate symp-
toms remission and prevent infection progression, at least
while the urine culture and antimicrobial sensistivity test-
ing are processed by the clinical laboratory. In Brazil, there
is a paucity of research in antimicrobial resistance of urinary
pathogens among adults in the community. Based on these
results, new studies are warranted to deﬁne the prevalence of
UTIs and clinical effectiveness of prescribed antibiotics.
In conclusion, out of the 136 analyzed isolates, E. coli and
S. aureus were the main species responsible for UTIs among
pregnant women in the study area. The most commonly
used antimicrobial agents in the sensitivity tests performed
by clinical laboratories included nalidixic acid, pipemidic
acid, cefadroxil, nitrofurantoin, amoxicillin, ampicillin, sulp-
hazotrim, ciproﬂoxacin, norﬂoxacin, and levoﬂoxacin, many
of which are contraindicated for pregnant women. Sensitivity
of isolated bacteria to fosfomycin was 89%, which indicates
that it might be an effective, safe and convenient therapeutic
option for the treatment of uncomplicated UTIs during preg-
nancy.
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